CUDC-101

CUDC-101CAS号: 1012054-59-9分子式: C24H26N4O4分子量: 434.49描述纯度储存/保存方法别名可溶性/溶解性靶点In vitro(体外研究)In vivo(体内研究)参考文献

产品描述
描述

CUDC-101是一种有效的,多靶点抑制剂,作用于HDAC,EGFR和HER2,IC50分别为4.4 nM, 2.4 nM,和15.7 nM,且抑制I/II型HDACs,但是对III型, Sir-type HDACs没有抑制作用。CUDC-101作为特异性抑制一类和二类HDACs家族的抑制剂,不能抑制第三类HDACs家族。CUDC-101还对其他的蛋白激酶包括KDR/VEGFR2, Lyn,,Lck, Abl-1, FGFR-2, Flt-3和 Ret具有微弱的抑制活性。IC50分别是0.85 μM,0.84 μM,5.91 μM,2.89 μM,3.43 μM,1.5 μM和 3.2 μM。

纯度
98%
储存/保存方法
Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution.
基本信息
别名
Curis
可溶性/溶解性
DMSO :16 mg/mL (36.8 mM)
生物活性
靶点
EGFR ,HDAC ,HDAC1 ,HDAC6 ,HDAC3
In vitro(体外研究)
Specific for class I and class II HDACs, CUDC-101 does not inhibit class III Sir-type HDACs. CUDC-101 displays weak activity against other protein kinases including KDR/VEGFR2, Lyn, Lck, Abl-1, FGFR-2, Flt-3, and Ret with IC50 of 0.85 μM, 0.84 μM, 5.91 μM, 2.89 μM, 3.43 μM, 1.5 μM, abd 3.2 μM, respectively. CUDC-101 displays broad antiproliferative activity in many human cancer cell types with IC50 of 0.04-0.80 μM, exhibiting a higher potency than erlotinib, lapatinib, and combinations of vorinostat with either erlotinib or lapatinib in most cases. CUDC-101 potently inhibits lapatinib- and erlotinib-resistant cancer cell lines. CUDC-101 inhibits the erlotinib-resistant EGFR mutant T790M although its effects are incomplete with an Amax of ~60% of peak enzyme activity after inhibition. CUDC-101 treatment increases the acetylation of histone H3 and H4, as well as the acetylation of non-histone substrates of HDAC such as p53 and α-tubulin, in a dose-dependant manner in various cancer cell lines. CUDC-101 also suppresses HER3 expression, Met amplification, and AKT reactivation in tumor cells.
In vivo(体内研究)
Administration of CUDC-101 at 120 mg/kg/day induces tumor regression in the Hep-G2 liver cancer model, which is more efficacious than that of erlotinib at its maximum tolerated dose (25 mg/kg/day) and vorinostat at an equimolar concentration dose (72 mg/kg/day). CUDC-101 inhibits the growth of erlotinib-sensitive H358 NSCLC xenografts in a dose-dependent manner. CUDC-101 also shows potent inhibition of tumor growth in the erlotinib-resistant A549 NSCLC xenograft model. CUDC-101 produces significant tumor regression in the lapatinib-resistant, HER2-negative, EGFR-overexpressing MDA-MB-468 breast cancer model and the EGFR-overexpressing CAL-27 head and neck squamous cell carcinoma (HNSCC) model. Additionally, CUDC-101 inhibits tumor growth in the K-ras mutant HCT116 colorectal and EGFR/HER2 (neu)-expressing HPAC pancreatic cancer models.
参考文献
参考文献
CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.
Laiet al. Cancer Res. 2010 May 1;70(9):3647-56. PMID:

分子结构图

CUDC-101